LC003422

4

6

7

8

9

10

11

12

13

14

15

16

17

18

19

STATE RHODE ISLAND OF

IN GENERAL ASSEMBLY

JANUARY SESSION, A.D. 2022

AN ACT

RELATING TO INSURANCE

Introduced By: Senators Lawson, DiMario, Burke, Murray, Cano, Quezada, and Valverde

Date Introduced: February 08, 2022

Referred To: Senate Health & Human Services

It is enacted by the General Assembly as follows:

1 SECTION 1. Chapter 27-18 of the General Laws entitled "Accident and Sickness Insurance 2 Policies" is hereby amended by adding thereto the following section:

27-18-89. Mandatory coverage for treatment of pediatric autoimmune 3 neuropsychiatric disorders associated with streptococcal infections and pediatric acute onset 5 neuropsychiatric syndrome.

(a) Every group health insurance contract, or every group hospital or medical expense insurance policy, plan, or group policy delivered, issued for delivery, or renewed in this state, by any health insurance carrier, on or after January 1, 2023, shall provide coverage for treatment of pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections and pediatric acute onset neuropsychiatric syndrome, including, but not limited to, the use of intravenous immunoglobin therapy.

(b) For billing and diagnosis purposes, pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections and pediatric acute onset neuropsychiatric syndrome shall be coded as autoimmune encephalitis until the American Medical Association and the Centers for Medicare and Medicaid Services create and assign a specific code for pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections and pediatric acute onset neuropsychiatric syndrome. Thereafter, pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections and pediatric acute onset neuropsychiatric syndrome may be coded as autoimmune encephalitis, pediatric autoimmune neuropsychiatric disorders associated

1	with streptococcal infections, or pediatric acute onset neuropsychiatric syndrome.
2	(c) The health care benefits outlined in this section apply only to services delivered within
3	the state of Rhode Island; provided, that all health insurance carriers shall be required to provide
4	coverage for those benefits mandated by this section outside of the state of Rhode Island where it
5	can be established through a pre-authorization process that the required services are not available
6	in the state of Rhode Island from a provider in the health insurance carrier's network.
7	(d) The office of the health insurance commissioner shall not allow the inclusion of the
8	cost of the benefit coverage provided in this section in the health insurance coverage rates proposed
9	to be charged, or a rating formula proposed to be used, by any health insurance carrier to policy
10	<u>holders.</u>
11	(e) Each health insurance carrier shall collect and provide to the office of the health
12	insurance commissioner, in a form and frequency acceptable to the commissioner, information and
13	data reflecting the costs and the savings of adding the benefit coverage provided in this section. On
14	or before January 1, 2025, the office of the health insurance commissioner shall report to the general
15	assembly a cost-benefit analysis of the implementation of the benefit coverage provided in this
16	section. The intent of this cost-benefit analysis is to determine if adding the benefit coverage
17	provided in this section produces a net savings to health insurance carriers and to policy holders.
18	(f) This section shall sunset and be repealed effective December 31, 2025.
19	SECTION 2. Chapter 27-19 of the General Laws entitled "Nonprofit Hospital Service
20	Corporations" is hereby amended by adding thereto the following section:
21	27-19-81. Mandatory coverage for treatment of pediatric autoimmune
22	neuropsychiatric disorders associated with streptococcal infections and pediatric acute onset
23	neuropsychiatric syndrome.
24	(a) Every group health insurance contract, or every group hospital or medical expense
25	insurance policy, plan, or group policy delivered, issued for delivery, or renewed in this state, by
26	any health insurance carrier, on or after January 1, 2023, shall provide coverage for treatment of
27	pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections and
28	pediatric acute onset neuropsychiatric syndrome, including, but not limited to, the use of
29	intravenous immunoglobin therapy.
30	(b) For billing and diagnosis purposes, pediatric autoimmune neuropsychiatric disorders
31	associated with streptococcal infections and pediatric acute onset neuropsychiatric syndrome shall
32	be coded as autoimmune encephalitis until the American Medical Association and the Centers for
33	Medicare and Medicaid Services create and assign a specific code for pediatric autoimmune
34	neuronsychiatric disorders associated with strentococcal infections and pediatric acute onset

1	neuropsychiatric syndrome. Thereafter, pediatric autoimmune neuropsychiatric disorders
2	associated with streptococcal infections and pediatric acute onset neuropsychiatric syndrome may
3	be coded as autoimmune encephalitis, pediatric autoimmune neuropsychiatric disorders associated
4	with streptococcal infections, or pediatric acute onset neuropsychiatric syndrome.
5	(c) The health care benefits outlined in this section apply only to services delivered within
6	the state of Rhode Island; provided, that all health insurance carriers shall be required to provide
7	coverage for those benefits mandated by this section outside of the state of Rhode Island where it
8	can be established through a pre-authorization process that the required services are not available
9	in the state of Rhode Island from a provider in the health insurance carrier's network.
10	(d) The office of the health insurance commissioner shall not allow the inclusion of the
11	cost of the benefit coverage provided in this section in the health insurance coverage rates proposed
12	to be charged, or a rating formula proposed to be used, by any health insurance carrier to policy
13	holders.
14	(e) Each health insurance carrier shall collect and provide to the office of the health
15	insurance commissioner, in a form and frequency acceptable to the commissioner, information and
16	data reflecting the costs and the savings of adding the benefit coverage provided in this section. On
17	or before January 1, 2025, the office of the health insurance commissioner shall report to the general
18	assembly a cost-benefit analysis of the implementation of the benefit coverage provided in this
19	section. The intent of this cost-benefit analysis is to determine if adding the benefit coverage
20	provided in this section produces a net savings to health insurance carriers and to policy holders.
21	(f) This section shall sunset and be repealed effective December 31, 2025.
22	SECTION 3. Chapter 27-20 of the General Laws entitled "Nonprofit Medical Service
23	Corporations" is hereby amended by adding thereto the following section:
24	27-20-77. Mandatory coverage for treatment of pediatric autoimmune
25	neuropsychiatric disorders associated with streptococcal infections and pediatric acute onset
26	neuropsychiatric syndrome.
27	(a) Every group health insurance contract, or every group hospital or medical expense
28	insurance policy, plan, or group policy delivered, issued for delivery, or renewed in this state, by
29	any health insurance carrier, on or after January 1, 2023, shall provide coverage for treatment of
30	pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections and
31	pediatric acute onset neuropsychiatric syndrome, including, but not limited to, the use of
32	intravenous immunoglobin therapy.
33	(b) For billing and diagnosis purposes, pediatric autoimmune neuropsychiatric disorders
34	associated with streptococcal infections and pediatric acute onset neuropsychiatric syndrome shall

1	be coded as autoimmune encephalitis until the American Medical Association and the Centers for
2	Medicare and Medicaid Services create and assign a specific code for pediatric autoimmune
3	neuropsychiatric disorders associated with streptococcal infections and pediatric acute onset
4	neuropsychiatric syndrome. Thereafter, pediatric autoimmune neuropsychiatric disorders
5	associated with streptococcal infections and pediatric acute onset neuropsychiatric syndrome may
6	be coded as autoimmune encephalitis, pediatric autoimmune neuropsychiatric disorders associated
7	with streptococcal infections, or pediatric acute onset neuropsychiatric syndrome.
8	(c) The health care benefits outlined in this section apply only to services delivered within
9	the state of Rhode Island; provided, that all health insurance carriers shall be required to provide
10	coverage for those benefits mandated by this section outside of the state of Rhode Island where it
11	can be established through a pre-authorization process that the required services are not available
12	in the state of Rhode Island from a provider in the health insurance carrier's network.
13	(d) The office of the health insurance commissioner shall not allow the inclusion of the
14	cost of the benefit coverage provided in this section in the health insurance coverage rates proposed
15	to be charged, or a rating formula proposed to be used, by any health insurance carrier to policy
16	<u>holders.</u>
17	(e) Each health insurance carrier shall collect and provide to the office of the health
18	insurance commissioner, in a form and frequency acceptable to the commissioner, information and
19	data reflecting the costs and the savings of adding the benefit coverage provided in this section. On
20	or before January 1, 2025, the office of the health insurance commissioner shall report to the general
21	assembly a cost-benefit analysis of the implementation of the benefit coverage provided in this
22	section. The intent of this cost-benefit analysis is to determine if adding the benefit coverage
23	provided in this section produces a net savings to health insurance carriers and to policy holders.
24	(f) This section shall sunset and be repealed effective December 31, 2025.
25	SECTION 4. Chapter 27-41 of the General Laws entitled "Health Maintenance
26	Organizations" is hereby amended by adding thereto the following section:
27	27-41-94. Mandatory coverage for treatment of pediatric autoimmune
28	neuropsychiatric disorders associated with streptococcal infections and pediatric acute onset
29	neuropsychiatric syndrome.
30	(a) Every group health insurance contract, or every group hospital or medical expense
31	insurance policy, plan, or group policy delivered, issued for delivery, or renewed in this state, by
32	any health insurance carrier, on or after January 1, 2023, shall provide coverage for treatment of
33	pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections and
34	pediatric acute onset neuropsychiatric syndrome, including, but not limited to, the use of

2	(b) For billing and diagnosis purposes, pediatric autoimmune neuropsychiatric disorders
3	associated with streptococcal infections and pediatric acute onset neuropsychiatric syndrome shall
4	be coded as autoimmune encephalitis until the American Medical Association and the Centers for
5	Medicare and Medicaid Services create and assign a specific code for pediatric autoimmune
6	neuropsychiatric disorders associated with streptococcal infections and pediatric acute onset
7	neuropsychiatric syndrome. Thereafter, pediatric autoimmune neuropsychiatric disorders
8	associated with streptococcal infections and pediatric acute onset neuropsychiatric syndrome may
9	be coded as autoimmune encephalitis, pediatric autoimmune neuropsychiatric disorders associated
10	with streptococcal infections, or pediatric acute onset neuropsychiatric syndrome.
11	(c) The health care benefits outlined in this section apply only to services delivered within
12	the state of Rhode Island; provided, that all health insurance carriers shall be required to provide
13	coverage for those benefits mandated by this section outside of the state of Rhode Island where it
14	can be established through a pre-authorization process that the required services are not available
15	in the state of Rhode Island from a provider in the health insurance carrier's network.
16	(d) The office of the health insurance commissioner shall not allow the inclusion of the
17	cost of the benefit coverage provided in this section in the health insurance coverage rates proposed
18	to be charged, or a rating formula proposed to be used, by any health insurance carrier to policy
19	holders.
20	(e) Each health insurance carrier shall collect and provide to the office of the health
21	insurance commissioner, in a form and frequency acceptable to the commissioner, information and
22	data reflecting the costs and the savings of adding the benefit coverage provided in this section. On
23	or before January 1, 2025, the office of the health insurance commissioner shall report to the general
24	assembly a cost-benefit analysis of the implementation of the benefit coverage provided in this
25	section. The intent of this cost-benefit analysis is to determine if adding the benefit coverage
26	provided in this section produces a net savings to health insurance carriers and to policy holders.
27	(f) This section shall sunset and be repealed effective December 31, 2025.

LC003422

28

1

intravenous immunoglobin therapy.

SECTION 5. This act shall take effect upon passage.

EXPLANATION

BY THE LEGISLATIVE COUNCIL

OF

AN ACT

RELATING TO INSURANCE

1	This act would require coverage for the treatment of pediatric autoimmune
2	neuropsychiatric disorders associated with streptococcal infections and pediatric acute onset
3	neuropsychiatric syndrome, including, but not limited to, the use of intravenous immunoglobin
4	therapy.
5	This act would take effect upon passage.
	LC003422